What is ARIAD Pharmaceuticals Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ARIAD Pharmaceuticals's interest expense for the
three
months ended in Sep. 2016 was $ -8.4 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Sep. 2016 was $-24.0 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ARIAD Pharmaceuticals's Operating Income for the
three
months ended in Sep. 2016 was $ -25.0 Mil. ARIAD Pharmaceuticals's Interest Expense for the
three
months ended in Sep. 2016 was $ -8.4 Mil.
ARIAD Pharmaceuticals did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
ARIAD Pharmaceuticals Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARIAD Pharmaceuticals (NAS:ARIA) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
ARIAD Pharmaceuticals's Interest Expense for the
three
months ended in Sep. 2016 was $-8.4 Mil. Its
Operating Income
for the
three
months ended in Sep. 2016 was $-25.0 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Sep. 2016 was $522.9 Mil.
ARIAD Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2016 is calculated as
| ARIAD Pharmaceuticals did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
ARIAD Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.
Executives
| Alexander J Denner |
director |
C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
| Norbert G Riedel |
director |
BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015 |
| Elona Esq. Kogan |
officer: Sr. V. P. - General Counsel |
C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065 |
| Manmeet Singh Soni |
officer: EVP, CFO & Treasurer |
C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085 |
| Timothy P Clackson |
officer: President, R&D, CSO |
C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Jules Haimovitz |
director |
601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004 |
| Daniel M Bollag |
officer: Sr. VP, Reg. Affairs & Quality |
C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Hugh M Cole |
officer: SVP, Chief Business Officer |
C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| George Bickerstaff |
director |
C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511 |
| Paris Panayiotopoulos |
director, officer: President and CEO |
ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Anna Protopapas |
director |
MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Sarah J. Schlesinger |
director |
C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Massimo Radaelli |
director |
C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Martin J Duvall |
officer: EVP, CCO |
MGI PHARMA, INC., 5775 WEST OLD SHAKOPEE ROAD, SUITE 100, BLOOMINGTON MN 55437 |
| Frank Haluska |
officer: SVP, Clinical R&D, CMO |
C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARIA has been successfully added to your 